GetTopicDetailResponse(id=05ee53e1af, topicName=CSU, introduction=CSU, content=null, image=null, comments=1, allHits=84, url=https://h5.medsci.cn/topic?id=5371, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=63143, tagList=[TagDto(tagId=63143, tagName=CSU)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2270578, encodeId=26bf22e057877, content=<a href='/topic/show?id=05ee53e1af' target=_blank style='color:#2F92EE;'>#CSU#</a>慢性自發(fā)性蕁麻疹（CSU）是一種無明顯外源性誘因的慢性炎癥性疾病，患者病情持續(xù)超過6周，表現(xiàn)為反復出現(xiàn)的皮膚風團和/或血管性水腫。, objectTitle=JAMA Dermatol：Rilzabrutinib在抗組胺藥難治性慢性自發(fā)性蕁麻疹中的應用與進展, objectType=article, longId=883937, objectId=762288393ea3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668024236648_4754896.jpeg, objectUrl=/article/show_article.do?id=762288393ea3, replyNumber=0, likeNumber=16, createdTime=2025-06-23, rootId=0, userName=ms4000001513304915, userId=a1646442901, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=廣東省, moduleDTOList=[ModuleDTO(moduleId=762288393ea3, moduleTitle=JAMA Dermatol：Rilzabrutinib在抗組胺藥難治性慢性自發(fā)性蕁麻疹中的應用與進展, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=762288393ea3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
前往app查看評論內(nèi)容
#CSU#慢性自發(fā)性蕁麻疹（CSU）是一種無明顯外源性誘因的慢性炎癥性疾病，患者病情持續(xù)超過6周，表現(xiàn)為反復出現(xiàn)的皮膚風團和/或血管性水腫。
